



HAL
open science

Signaling through LRP1: Protection from atherosclerosis and beyond

Philippe Boucher, Joachim Herz

► **To cite this version:**

Philippe Boucher, Joachim Herz. Signaling through LRP1: Protection from atherosclerosis and beyond. *Biochemical Pharmacology*, 2010, 81 (1), pp.1. 10.1016/j.bcp.2010.09.018 . hal-00642415

HAL Id: hal-00642415

<https://hal.science/hal-00642415>

Submitted on 18 Nov 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Signaling through LRP1: Protection from atherosclerosis and beyond

Authors: Philippe Boucher, Joachim Herz

PII: S0006-2952(10)00701-X
DOI: doi:10.1016/j.bcp.2010.09.018
Reference: BCP 10723

To appear in: *BCP*

Received date: 27-7-2010
Revised date: 14-9-2010
Accepted date: 20-9-2010

Please cite this article as: Boucher P, Herz J, Signaling through LRP1: Protection from atherosclerosis and beyond, *Biochemical Pharmacology* (2010), doi:10.1016/j.bcp.2010.09.018

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Signaling through LRP1: Protection from atherosclerosis and beyondPhilippe Boucher¹, Joachim Herz²

From ¹CNRS, UMR7175, Université de Strasbourg, Illkirch, F-67401 France and ²Department of Molecular Genetics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9046.

Address correspondence to: CNRS, UMR7175, Université de Strasbourg, 74, route du Rhin, Illkirch, F-67401 France. Tel: +33 3 6885 4149; Fax: +33 3 6885 4313;
E-mail: philippe.boucher@pharma.u-strasbg.fr

ABSTRACT

1
2
3
4 The low-density lipoprotein receptor-related protein (LRP1) is a multifunctional cell
5 surface receptor that belongs to the LDL receptor (LDLR) gene family and that is widely
6 expressed in several tissues. LRP1 consists of an 85-KDa membrane-bound carboxyl
7 fragment (β chain) and a non-covalently attached 515-KDa (α chain) amino-terminal
8 fragment. Through its extracellular domain, LRP1 binds at least 40 different ligands ranging
9 from lipoprotein and protease inhibitor complex to growth factors and extracellular matrix
10 proteins. LRP-1 has also been shown to interact with scaffolding and signaling proteins via its
11 intracellular domain in a phosphorylation-dependent manner and to function as a co-receptor
12 partnering with other cell surface or integral membrane proteins. LRP-1 is thus implicated in
13 two major physiological processes: endocytosis and regulation of signaling pathways, which
14 are both involved in diverse biological roles including lipid metabolism, cell
15 growth/differentiation processes, degradation of proteases, and tissue invasion. The
16 embryonic lethal phenotype obtained after target disruption of the LRP-1 gene in the mouse
17 highlights the biological importance of this receptor and revealed a critical, but yet undefined
18 role in development. Tissue-specific gene deletion studies also reveal an important
19 contribution of LRP1 in vascular remodeling, foam cell biology, the central nervous system,
20 and in the molecular mechanisms of atherosclerosis.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 LRP1 (also known as CD91, or α 2macroglobulin receptor, α 2MR) is a ubiquitously
2 expressed type 1 transmembrane receptor [1]. The mature form of the receptor is derived from
3 a 600-kDa precursor that is proteolytically processed upon furin cleavage. The processed form
4 of the receptor consists of a carboxyl-terminal β -fragment of 85-kDa, which contains an
5 intracellular and a transmembrane domain. The extracellular portion of the 85 kDa fragment
6 is non-covalently connected to the large amino-terminal 515-kDa α -fragment, which harbors
7 several ligand binding domains that interact with multiple LRP1 ligands (Figure1) [1, 2].
8
9

10 LRP1 is the most multifunctional member of the LDL receptor gene family [3]. It has
11 been implicated in two main biological functions: endocytosis of its numerous ligands and
12 regulation of cell signaling pathways. Through its extracellular domain, LRP1 interacts with
13 at least 40 different ligands ranging from lipoproteins, extracellular matrix glycoproteins,
14 protease/inhibitor complexes, viruses, cytokines and growth factors (Table 1). The large
15 variety of ligands LRP1 recognizes reflects the numerous biological functions this
16 evolutionarily ancient receptor has adopted since its inception in the most primitive
17 metazoans. Its ubiquitous expression, the remarkable structural and sequence conservation
18 among species, the absence of any known functional coding mutations of the LRP1 gene in
19 humans, and the lethality of the conventional knockout in mice reveal that LRP1 is
20 indispensable for cellular physiology.
21
22

23 Besides its role in endocytosis [3, 4], several studies have shown that LRP1 is essential
24 for multiple signaling pathways. These functions have been described in the vascular wall, in
25 neurons, adipose tissue, and numerous other tissues. In the vascular wall, LRP1 plays a major
26 role in controlling vascular smooth muscle cells (vSMCs) proliferation, and protects against
27 atherosclerosis. Mice lacking LRP1 in vSMCs exhibit hyperplasia of the aortic wall,
28 disruption of the elastic lamina, aortic aneurysm formation and greatly enhanced
29 susceptibility to atherosclerotic lesion development [5]. LRP1-deficient mice fed a high
30 cholesterol diet develop massive foam cell formation within the arterial wall, leading to the
31 complete occlusion of the lumen of the aorta and the mesenteric arteries, and thus the death of
32 the animals from progressive large vessel obstruction. The mechanism by which LRP1
33 protects against the formation of atherosclerotic lesions is mediated through control of at least
34 two distinct signaling pathways in vSMCs by the receptor: the platelet-derived growth factor
35 BB (PDGF-BB) and the transforming growth factor- β (TGF β) signaling pathways, which
36 both play major roles during atherosclerosis [5-7]. Excessive smooth muscle hyperplasia of
37 the aorta associated with LRP1-deficiency is accompanied by a major increase in the
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

expression of the PDGF receptor β (PDGFR β), increased PDGFR β phosphorylation, and increased phosphorylation of Smad2, a downstream component of the TGF β pathway that mediates the TGF β transcriptional response. The PDGF-BB pathway has been previously described as a target of the TGF β signaling pathway [8-10]. Moreover, LRP1 is identical to the TGF β receptor (V), a member of the TGF β receptor superfamily that is expressed together with TGF β receptor I, II and III at the cell surface [11]. Thus, activation of the TGF β pathway in the absence of LRP1 can further activate the PDGF-BB signaling pathway, by increasing the expression of PDGFR β in the arterial wall and thereby promoting atherosclerotic lesion formation.

Macrophage lipoprotein receptors can accelerate progression of atherosclerosis by facilitating uptake of atherogenic particles such as the oxidized lipoproteins [12]. In the particular case of LRP1, deletion of the receptor in macrophages has also been shown to increase atherosclerosis in mice [13]. Transplantation of macrophage LRP1 $^{-/-}$ bone marrow into lethally irradiated female LDLR $^{-/-}$ recipient mice resulted in a 40% increase in atherosclerosis [13]. Deletion of LRP1 in macrophages however, did not alter plasma lipid levels or plasma lipoprotein profiles, demonstrating no significant contribution of macrophage LRP1-mediated remnant clearance in influencing plasma lipoprotein levels *in vivo*. LRP1 $^{-/-}$ macrophages displayed increased expression of proinflammatory cytokines such as IL-1 β , IL-6 and tumor necrosis factor- α expression, and suppression of the pAkt survival pathway [14]. Thus, macrophage LRP1 might protect against atherosclerosis by decreasing inflammation, but also by facilitating efferocytosis, an atheroprotective effect by which apoptotic cells are removed from the lesions by phagocytic cells [13-15].

Since LRP1 in the liver participates in the removal of atherogenic apoE rich lipoproteins from the circulation, its role in that tissue during atherogenesis has also been investigated. Hepatic LRP1 plays a clear protective role in atherogenesis but independent of plasma cholesterol [16]. The mechanism by which hepatic LRP1 affects the development of atherosclerotic lesions is not clear. It might involve clearance of other LRP1 ligands that are related to atherosclerosis such as t-PA or u-PA.

Recently, we have shown that LRP1 is required for normal signaling through a canonical Wnt5a dependent pathway in mouse embryonic fibroblasts (MEF), and that activation of this pathway prevents intracellular cholesterol accumulation, a prominent and necessary feature of the atherosclerotic lesion formation [17]. LRP1 also regulates LXR-mediated gene transcription and participates in reverse cholesterol transport by controlling

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

cPLA2 activation and ABCA1 expression [18]. LRP1 is further required for lipolysis and for the stimulation of fatty acid synthesis independent of noradrenergic signals, through inhibition of GSK3 β and its previously unknown target acetyl-CoA carboxylase (ACC) [17]. LRP1 thus, functions as a physiological integrator of cellular lipid homeostasis with signals that regulate cellular proliferation and vascular wall integrity.

Besides its large contribution to the protection against atherosclerosis, recent work has also shown a role for LRP1 and one of its ligands, tissue plasminogen activator (tPA), in the regulation of vascular tone [19] and the permeability of the blood brain barrier permeability (BBB) [20]. tPA regulates vascular contractility through LRP1 and this is reversed by a physiological tPA inhibitor, plasminogen activator inhibitor 1 (PAI-1). The authors reported that vasoconstriction induced by tPA requires a functional interaction between LRP1 and alpha(v)beta(3) integrin [21]. The mechanism of this interaction and the signaling pathways involved, however, remain unknown. Regulation of BBB permeability is important for neuronal homeostasis and protects the brain against toxins that constantly enter the circulation from the external environment and through the gut. The authors demonstrate that tPA directly induces BBB permeability and that this is blocked by anti-LRP1 antibodies and by the receptor-associated protein (RAP), a chaperone protein that blocks the binding of most of the known LRP1 ligands. These results thus suggest that the tPA-dependent regulation of BBB permeability requires the expression of LRP1 [20].

LRP1 is also playing an important role in the central nervous system (CNS), especially in neurons where it is highly expressed [22, 23] and where it interacts with numerous neuronal proteins such as the postsynaptic density protein 95 (PSD-95) and the N-methyl-D-aspartate (NMDA) receptor [24]. In the brain, glutamate is the main excitatory neurotransmitter, which also plays an important role in neuronal cell death in neurodegenerative diseases [25, 26]. Moreover, LRP1 has been shown to regulate calcium signaling *in vitro* [27], an important second messenger during glutamate neurotransmission. The active form of α 2-macroglobulin (α 2M), an LRP1 ligand, inhibits the calcium-dependent NMDA response and the expression of NMDA receptors through a signaling pathway involving LRP1 [28]. Mice lacking LRP1 in neurons exhibit a severe movement disorder, hyperactivity, and premature death [24].

In the lung, a new important role for LRP1 in the course of the inflammatory response has been reported [29]. The authors described that in the absence of LRP1, the surfactant proteins A and D (SP-A et SP-D) bind to the signal inhibitory regulatory protein α (SIRP α). This activates the tyrosine phosphatase SHP-1, blocks Src family kinases and p38 MAP

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

kinases, and thereby inhibits the inflammatory response. By contrast, when LRP1 is expressed, surfactant proteins SP-A and SP-D interact with foreign organisms, apoptotic cells or cell debris, and the presentation of these organisms to LRP1 in macrophages by calreticulin leads to their phagocytosis and inflammatory response in lungs. Interestingly, it has been proposed that adiponectin promotes the uptake of apoptotic debris by peritoneal macrophages via a calreticulin/LRP1 pathway but not through the previously identified adiponectin receptor [30]. Thus, LRP1 is an important component that regulates the initiation of the innate immune response. This function of LRP1 in macrophages is not only important in lung macrophages, but has also implications in other tissues such as the aortas and in clearance of cells that have undergone apoptosis [31] an important physiologic function during development and tissue homeostasis [32].

As is the case for numerous receptor and membrane proteins, the extracellular domain of LRP1 can be cleaved by cell surface proteases and subsequently released into the extracellular space or the circulation. A circulating form of LRP1 has been found at nM concentration in human plasma [33, 34]. This cleaved form of LRP1 contains the α chain of about 515 kDa and a fragment of the β chain (85 kDa) of about 55 kDa, demonstrating that the cleavage occurs close to the plasma membrane [33]. Enzymes that can mediate this cleavage have been identified and include the neuronal BACE1 protease [35] and a hepatic metalloproteinase [33]. The LRP1 soluble form is present in the plasma of mammals, but also in the blood of birds, and reptiles. In most case the physiological meaning of the extracellular cleavage is not certain, but since the soluble form can still bind most of the LRP1 ligands and thereby reduce their endocytosis by cellular LRP1, the soluble fragment may serve to quench extracellular ligand interaction with the cell or regulate their intracellular trafficking.

Several of the mechanisms by which LRP1 controls cell signaling pathways remain unresolved. One potential mechanism involves the cleavage of the transmembrane domain of the LRP1 β chain by regulated intramembraneous proteolysis (RIP). The released fragment (LRP1-ICD) of approximately 12 kDa might thus translocate to the nucleus where it can regulate the transcription of target genes [36]. RIP is a process by which the first step of proteolysis involves an extracellular cleavage event, which is then followed by intramembraneous processing and the release of a, usually small, cytoplasmic fragment that may have functions in the cytoplasm or in the nucleus, including transcriptional regulation [37]. Several proteins including the amyloid precursor protein (APP), Notch, a transmembrane protein that regulates cell fate decision of ES cells during development, the tyrosine kinase receptor ErbB-4 [38], the receptor CD44 [39], sterol regulatory element

1 binding proteins SREBPs [40], ATF6 [41], Ire1[42], and cadherin [43] function through a RIP
2 mechanism. In most cases, the intramembranous cleavage is done by the presenilin (PS)/ γ -
3 secretase complex. In the case of LRP1, the intracellular domain can also be released upon
4 proteolytic cleavage by the presenilin (PS)/ γ -secretase complex [36]. However, the precise
5 cleavage site and thus the complete sequence of the released fragment remain unknown.
6
7 Recently, one potential target of the LRP1-ICD has been identified [44]. Lipopolysaccharide
8 (LPS) increases the proteolytic processing of the ectodomain of LRP1, which results in the γ -
9 secretase-dependent release of the LRP1 intracellular domain (ICD) from the plasma
10 membrane and its subsequent translocation to the nucleus, where it interacts with and
11 represses the interferon- γ promoter [44]. The LRP1-ICD fragment contains numerous motifs
12 that have been implicated in numerous signaling pathways: Two NPXY motifs, where the
13 distal motif is contiguous with a YXXL motif, and two dileucine motifs. The YXXL motif is
14 presumably the most important one mediating LRP1 endocytosis [45]. However, both NPXY
15 motifs can bind and interact with numerous cytosolic proteins such as, DAB1, FE65, JIP1,
16 PSD-95, ShcA or CED-6/GULP [6, 7, 46-50]. *In vitro* studies have shown that the LRP1-ICD
17 can colocalize with the histone acetyl transferase Tip60 in the nucleus [51], which in turn can
18 regulate transcription upon APP cleavage [52, 53] suggesting that the LRP1-ICD might be
19 able to regulate the transcriptional activity of the APP-Tip60 complex, and thus have a more
20 general function as a regulator of transcription. In order to dissect the *in vivo* functions of
21 each motifs located in the LRP-ICD, Roebroek and colleagues [54] introduced mutations into
22 the furin cleavage site and into both NPXY motifs located in the cytoplasmic tail of LRP1.
23 Mutation of the NPXY motif of the cytoplasmic domain or in the furin cleavage site caused
24 distinctive liver phenotypes: respectively, either a late fetal destruction of the organ causing
25 perinatal death or a selective enlargement of von-Kupffer cell lysosomes reminiscent of a
26 mild lysosomal storage without an apparent negative effect on animal survival. A mutation of
27 the most distal NPXY motif within the cytoplasmic tail of LRP1 did not exhibit an overt
28 phenotype [54].

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

In conclusion, LRP1 is a large multifunctional receptor with two main biological functions in multiple ligand endocytosis and in the control and integration of intercellular signaling pathways, which are not required for survival of the cell per se, but essential for the maintenance of basal cellular function and development and survival of the organism. Indicative of its importance, LRP1 is expressed in almost all cells, and there is no known disease-related LRP1 coding mutation that has been described in humans to date. Since it

1 participates in such a large number of physiological activities as a co-receptor and also by
2 interacting with numerous adaptor proteins through its cytoplasmic domain, functional
3 dissection of these mechanisms and identification of further LRP1 partners might open new
4 avenues to the treatment of metabolic diseases such as lipid metabolism and atherosclerosis,
5 but also inflammation, Alzheimer disease and obesity.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Accepted Manuscript

REFERENCES

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [1] Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. *Embo J* 1988;7:4119-27.
 - [2] Willnow TE, Hilpert J, Armstrong SA, Rohlmann A, Hammer RE, Burns DK, et al. Defective forebrain development in mice lacking gp330/megalin. *Proc Natl Acad Sci U S A* 1996;93:8460-4.
 - [3] Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. *J Clin Invest* 2001;108:779-84.
 - [4] Lillis AP, Mikhailenko I, Strickland DK. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. *J Thromb Haemost* 2005;3:1884-93.
 - [5] Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J. LRP: role in vascular wall integrity and protection from atherosclerosis. *Science* 2003;300:329-32.
 - [6] Boucher P, Liu P, Gotthardt M, Hiesberger T, Anderson RG, Herz J. Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low Density lipoprotein receptor-related protein in caveolae. *J Biol Chem* 2002;277:15507-13.
 - [7] Loukinova E, Ranganathan S, Kuznetsov S, Gorlatova N, Migliorini MM, Loukinov D, et al. Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function between LRP and the PDGF. *J Biol Chem* 2002;277:15499-506.
 - [8] Bategay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. *Cell* 1990;63:515-24.
 - [9] Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. *Curr Opin Rheumatol* 2002;14:681-5.
 - [10] Taylor LM, Khachigian LM. Induction of platelet-derived growth factor B-chain expression by transforming growth factor-beta involves transactivation by Smads. *J Biol Chem* 2000;275:16709-16.
 - [11] Huang SS, Leal SM, Chen C-L, Liu IH, Huang JS. Identification of insulin receptor substrate proteins as key molecules for the TβR-V/LRP-1-mediated growth inhibitory signaling cascade in epithelial and myeloid cells. *FASEB J* 2004;04-1872fje.
 - [12] Linton MF, Babaev VR, Gleaves LA, Fazio S. A direct role for the macrophage low density lipoprotein receptor in atherosclerotic lesion formation. *J Biol Chem* 1999;274:19204-10.
 - [13] Overton CD, Yancey PG, Major AS, Linton MF, Fazio S. Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mouse. *Circ Res* 2007;100:670-7.
 - [14] Yancey PG, Blakemore J, Ding L, Fan D, Overton CD, Zhang Y, et al. Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. *Arterioscler Thromb Vasc Biol* 2010;30:787-95.
 - [15] Thorp E, Tabas I. Mechanisms and consequences of efferocytosis in advanced atherosclerosis. *J Leukoc Biol* 2009;86:1089-95.
 - [16] Espirito Santo SM, Pires NM, Boesten LS, Gerritsen G, Bovenschen N, van Dijk KW, et al. Hepatic low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol. *Blood* 2004;103:3777-82.

- 1 [17] Terrand J, Bruban V, Zhou L, Gong W, El Asmar Z, May P, et al. LRP1 controls
2 intracellular cholesterol storage and fatty acid synthesis through modulation of Wnt
3 signaling. *J Biol Chem* 2009;284:381-8.
- 4 [18] Zhou L, Choi HY, Li WP, Xu F, Herz J. LRP1 controls cPLA2 phosphorylation,
5 ABCA1 expression and cellular cholesterol export. *PLoS One* 2009;4:e6853.
- 6 [19] Nassar T, Akkawi S, Shina A, Haj-Yehia A, Bdeir K, Tarshis M, et al. In vitro and in
7 vivo effects of tPA and PAI-1 on blood vessel tone. *Blood* 2004;103:897-902.
- 8 [20] Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-
9 type plasminogen activator induces opening of the blood-brain barrier via the LDL
10 receptor-related protein. *J Clin Invest* 2003;112:1533-40.
- 11 [21] Akkawi S, Nassar T, Tarshis M, Cines DB, Higazi AA. LRP and α v β 3
12 mediate tPA activation of smooth muscle cells. *Am J Physiol Heart Circ Physiol*
13 2006;291:H1351-9.
- 14 [22] Bu G, Maksymovitch EA, Geuze H, Schwartz AL. Subcellular localization and
15 endocytic function of low density lipoprotein receptor-related protein in human
16 glioblastoma cells. *J Biol Chem* 1994;269:29874-82.
- 17 [23] Bu G, Maksymovitch EA, Nerbonne JM, Schwartz AL. Expression and function of the
18 low density lipoprotein receptor-related protein (LRP) in mammalian central neurons.
19 *J Biol Chem* 1994;269:18521-8.
- 20 [24] May P, Rohlmann A, Bock HH, Zurhove K, Marth JD, Schomburg ED, et al.
21 Neuronal LRP1 functionally associates with postsynaptic proteins and is required for
22 normal motor function in mice. *Mol Cell Biol* 2004;24:8872-83.
- 23 [25] Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegeneration in Alzheimer
24 disease. New hypothesis and new therapeutic strategies. *Arch Neurol* 1997;54:1234-
25 40.
- 26 [26] Olney JW, Wozniak DF, Farber NB. Glutamate receptor dysfunction and Alzheimer's
27 disease. *Restor Neurol Neurosci* 1998;13:75-83.
- 28 [27] Bacskai BJ, Xia MQ, Strickland DK, Rebeck GW, Hyman BT. The endocytic receptor
29 protein LRP also mediates neuronal calcium signaling via N-methyl-D-aspartate
30 receptors. *Proc Natl Acad Sci U S A* 2000;97:11551-6.
- 31 [28] Qiu Z, Strickland DK, Hyman BT, Rebeck GW. α 2-Macroglobulin exposure
32 reduces calcium responses to N-methyl-D-aspartate via low density lipoprotein
33 receptor-related protein in cultured hippocampal neurons. *J Biol Chem*
34 2002;277:14458-66.
- 35 [29] Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE, et al. By
36 binding SIRP α or calreticulin/CD91, lung collectins act as dual function
37 surveillance molecules to suppress or enhance inflammation. *Cell* 2003;115:13-23.
- 38 [30] Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer RS, et al.
39 Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent
40 clearance of early apoptotic bodies. *J Clin Invest* 2007;117:375-86.
- 41 [31] Patel M, Morrow J, Maxfield FR, Strickland DK, Greenberg S, Tabas I. The
42 cytoplasmic domain of the low density lipoprotein (LDL) receptor-related protein, but
43 not that of the LDL receptor, triggers phagocytosis. *J Biol Chem* 2003;278:44799-807.
- 44 [32] Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE,
45 et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through
46 trans-activation of LRP on the phagocyte. *Cell* 2005;123:321-34.
- 47 [33] Quinn KA, Pye VJ, Dai YP, Chesterman CN, Owensby DA. Characterization of the
48 soluble form of the low density lipoprotein receptor-related protein (LRP). *Exp Cell*
49 *Res* 1999;251:433-41.
- 50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [34] Quinn KA, Grimsley PG, Dai YP, Tapner M, Chesterman CN, Owensby DA. Soluble
2 low density lipoprotein receptor-related protein (LRP) circulates in human plasma. *J*
3 *Biol Chem* 1997;272:23946-51.
- 4 [35] von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, et al. The low
5 density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1)
6 substrate. *J Biol Chem* 2005;280:17777-85.
- 7 [36] May P, Reddy YK, Herz J. Proteolytic processing of low density lipoprotein receptor-
8 related protein mediates regulated release of its intracellular domain. *J Biol Chem*
9 2002;277:18736-43.
- 10 [37] Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a
11 control mechanism conserved from bacteria to humans. *Cell* 2000;100:391-8.
- 12 [38] Ni CY, Murphy MP, Golde TE, Carpenter G. gamma -Secretase cleavage and nuclear
13 localization of ErbB-4 receptor tyrosine kinase. *Science* 2001;294:2179-81.
- 14 [39] Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T, et al. Proteolytic
15 release of CD44 intracellular domain and its role in the CD44 signaling pathway. *J*
16 *Cell Biol* 2001;155:755-62.
- 17 [40] Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism
18 by proteolysis of a membrane-bound transcription factor. *Cell* 1997;89:331-40.
- 19 [41] Haze K, Yoshida H, Yanagi H, Yura T, Mori K. Mammalian transcription factor
20 ATF6 is synthesized as a transmembrane protein and activated by proteolysis in
21 response to endoplasmic reticulum stress. *Mol Biol Cell* 1999;10:3787-99.
- 22 [42] Niwa M, Sidrauski C, Kaufman RJ, Walter P. A role for presenilin-1 in nuclear
23 accumulation of Ire1 fragments and induction of the mammalian unfolded protein
24 response. *Cell* 1999;99:691-702.
- 25 [43] Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, et al. A
26 presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain
27 and regulates disassembly of adherens junctions. *Embo J* 2002;21:1948-56.
- 28 [44] Zurhove K, Nakajima C, Herz J, Bock HH, May P. Gamma-secretase limits the
29 inflammatory response through the processing of LRP1. *Sci Signal* 2008;1:ra15.
- 30 [45] Li Y, Marzolo MP, van Kerkhof P, Strous GJ, Bu G. The YXXL motif, but not the
31 two NPXY motifs, serves as the dominant endocytosis signal for low density
32 lipoprotein receptor-related protein. *J Biol Chem* 2000;275:17187-94.
- 33 [46] Barnes H, Larsen B, Tyers M, van Der Geer P. Tyrosine-phosphorylated low density
34 lipoprotein receptor-related protein 1 (Lrp1) associates with the adaptor protein SHC
35 in SRC-transformed cells. *J Biol Chem* 2001;276:19119-25.
- 36 [47] Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, et
37 al. Interactions of the low density lipoprotein receptor gene family with cytosolic
38 adaptor and scaffold proteins suggest diverse biological functions in cellular
39 communication and signal transduction. *J Biol Chem* 2000;275:25616-24.
- 40 [48] Su HP, Nakada-Tsukui K, Tosello-Tramont AC, Li Y, Bu G, Henson PM, et al.
41 Interaction of CED-6/GULP, an adapter protein involved in engulfment of apoptotic
42 cells with CED-1 and CD91/low density lipoprotein receptor-related protein (LRP). *J*
43 *Biol Chem* 2002;277:11772-9.
- 44 [49] Trommsdorff M, Borg JP, Margolis B, Herz J. Interaction of cytosolic adaptor
45 proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. *J*
46 *Biol Chem* 1998;273:33556-60.
- 47 [50] Chang Y, Tesco G, Jeong WJ, Lindsley L, Eckman EA, Eckman CB, et al. Generation
48 of the beta-amyloid peptide and the amyloid precursor protein C-terminal fragment
49 gamma are potentiated by FE65L1. *J Biol Chem* 2003;278:51100-7.
- 50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [51] Kinoshita A, Shah T, Tangredi MM, Strickland DK, Hyman BT. The intracellular
2 domain of the low density lipoprotein receptor-related protein modulates
3 transactivation mediated by amyloid precursor protein and Fe65. *J Biol Chem*
4 2003;278:41182-8.
- 5 [52] Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG. Exchange of N-
6 CoR corepressor and Tip60 coactivator complexes links gene expression by NF-
7 kappaB and beta-amyloid precursor protein. *Cell* 2002;110:55-67.
- 8 [53] Cao X, Sudhof TC. A transcriptionally [correction of transcriptively] active complex
9 of APP with Fe65 and histone acetyltransferase Tip60. *Science* 2001;293:115-20.
- 10 [54] Roebroek AJ, Reekmans S, Lauwers A, Feyaerts N, Smeijers L, Hartmann D. Mutant
11 Lrp1 knock-in mice generated by recombinase-mediated cassette exchange reveal
12 differential importance of the NPXY motifs in the intracellular domain of LRP1 for
13 normal fetal development. *Mol Cell Biol* 2006;26:605-16.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

FOOTNOTES

1
2
3 This work was supported by grants from, centre national pour la recherche scientifique
4 (CNRS), University of Strasbourg, Fondation de France, agence nationale de la recherche
5 (ANR-06-PHYSIO-032-01, and ANR-09-BLAN-0121-01), the National Institutes of Health,
6 the American Health Assistance Foundation, the Perot Family Foundation, the Consortium for
7 Frontotemporal Dementia Research (CFR) and the Wolfgang-Paul Program of the Humboldt
8 Foundation.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

FIGURE LEGENDS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1.

The low-density lipoprotein receptor-related protein (LRP1). LRP1 is a multifunctional receptors that binds a large spectrum of extracellular and intracellular ligands. The extracellular domain consists of ligand-binding-type repeats organized in four binding domains (DI, DII, DIII, DIV) and epidermal precursor homology domains, which contain YWTD repeats and EGF repeats. The cytoplasmic tail of the receptor is containing cytoplasmic NPxY motifs that mediate protein– protein interactions required for endocytosis as well as for the assembly of scaffold proteins related to signal transduction and trafficking such as Dab1, Fe65, JIP1, omp25, and integrin cytoplasmic domain-associated protein 1.

TABLE 1: LRP1 known ligands

Proteins involved in lipoprotein metabolism

Apolipoprotein E-enriched lipoproteins (chylomicron and VLDL remnants),
Lipoprotein lipase (LPL), Hepatic lipase, Sphingolipid activator protein

Proteases and protease/inhibitor complexes

Activated α_2 -macroglobulin, α_2 -macroglobulin protease complexes, Pregnancy zone protein-protease complexes, Aprotinin, urokinase plasminogen activator (uPA), pro-uPA, plasminogen activator inhibitor (PAI-1), uPA/PAI-1 complexes, tissue-type plasminogen activator (tPA), tPA/PAI-1 complexes, Thrombin/PA-1, Thrombin/anti-thrombin III, Thrombin/protease nexin-1, Thrombin/heparin cofactor II, Neuroserpin, Neuroserpin /tPA complexes, C1s/C1q inhibitor, Protease/protein C inhibitor, Elastase/ α_1 -anti-trypsin, MMP-9, MMP-13, TSP-2/MMP-2 complexes, Tissue factor pathway inhibitor (TFPI), Factor VIIa/TFPI, Factor VIIIa, Factor IXa, Factor IXa/protease nexin-1, β -amyloid precursor protein

Matrix proteins

Thrombospondin-1, Thrombospondin-2, Fibronectin

Intracellular proteins

Receptor associated protein (RAP), Calreticulin, HIV Tat protein

Growth factors

Platelet-derived growth factor (PDGF), Midkine, Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), Connective tissue growth factor (CTGF/CCN2), Transforming growth factor (TGF- β)

Others

Circumsporozoite protein, Lactoferrin, Ricin A, Saposin, Rhinovirus A peptide (monomer), Gentamicin, Polymycin B, Pseudomonas exotoxin A, Complement C3, Collectins (via calreticulin)




Figure 1

TABLE 1. Ligands known to bind to LRP1

Proteins involved in lipoprotein metabolism

Apolipoprotein E-enriched lipoproteins (chylomicron and VLDL remnants), Lipoprotein lipase (LPL), Hepatic lipase, Sphingolipid activator protein.

Proteases and protease/inhibitor complexes

Activated α_2 -Macroglobulin, α_2 -Macroglobulin protease complexes, Pregnancy zone protein-protease complexes, Aprotinin, pro-uPA, uPA, uPA/PAI-1 complexes, tPA, PAI-1, tPA/PAI-1 complexes, Thrombin/PAI-1, Thrombin/anti-thrombin III, Thrombin/protease nexin-1, Thrombin/heparin cofactor II, Neuroserpin, Neuroserpin/tPA complexes, C1s/C1q inhibitor, Protease/protein C inhibitor, Elastase/ α_1 -anti-trypsin, MMP-9, MMP-13, TSP-2/MMP-2 complexes, Tissue factor pathway inhibitor (TFPI), Factor VIIa/TFPI, Factor VIIIa, Factor IXa, Factor IXa/protease nexin-1, β -amyloid precursor protein.

Matrix proteins

Thrombospondin-1, Thrombospondin-2, Fibronectin.

Intracellular proteins

Receptor-associated protein (RAP), Calreticulin, HIV Tat protein.

Growth factors


Platelet-derived growth factor (PDGF), Midkine, Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), Connective tissue growth factor (CTGF/CCN2), Transforming growth factor (TGF β).

Others

Circumsporozoite protein, Lactoferrin, Ricin A, Saposin, Rhinovirus A peptide (monomer), Gentamicin, Polymycin B, Pseudomonas exotoxin A, Complement C3, Collectins (via calreticulin).

Figure 1
[Click here to download high resolution image](#)

-  Ligand binding repeat
-  EGF repeat
-  NPxY motif
-  Spacer region





trip


LRP1

Endocytosis

Cell Signaling



Vascular remodeling



Cholesterol homeostasis